Editorial: Cancer treatment-related cardiovascular disease - real world data in cardio-oncology.
作者信息
Agarwala Vivek, Ghosh Arjun, Guha Avirup, Parikh Purvish M, Dent Susan
机构信息
Medical Oncology & Hemat-Oncology, Narayana Superspeciality Hospital & Cancer Institute, Howrah and RN Tagore International Institute of Cardiac Sciences (RTIICS), Kolkata, India.
Cardiology, Barts Heart Centre and University College London Hospital, London, United Kingdom.
出版信息
Front Oncol. 2023 Sep 20;13:1277042. doi: 10.3389/fonc.2023.1277042. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Cancer treatment-related cardiovascular disease - real world data in cardio-oncology.
Front Oncol. 2023 Sep 20;13:1277042. doi: 10.3389/fonc.2023.1277042. eCollection 2023.
2
Long-term and real-life incidence of cancer therapy-related cardiovascular toxicity in patients with breast cancer: a Swedish cohort study.
Front Oncol. 2023 Apr 19;13:1095251. doi: 10.3389/fonc.2023.1095251. eCollection 2023.
3
Global longitudinal strain at 3 months after therapy can predict late cardiotoxicity in breast cancer.
Cancer Med. 2023 Jun;12(12):13374-13387. doi: 10.1002/cam4.6039. Epub 2023 May 15.
4
Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity.
Clin Transl Oncol. 2023 Nov;25(11):3073-3085. doi: 10.1007/s12094-023-03217-2. Epub 2023 May 25.
5
Advanced Echocardiographic Techniques in Cardio-Oncology: the Role for Early Detection of Cardiotoxicity.
Curr Cardiol Rep. 2022 Sep;24(9):1109-1116. doi: 10.1007/s11886-022-01728-y. Epub 2022 Jul 26.
6
Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward?
J Oncol Pharm Pract. 2023 Apr;29(3):646-662. doi: 10.1177/10781552221077417. Epub 2022 Feb 15.
7
Modeling Precision Cardio-Oncology: Using Human-Induced Pluripotent Stem Cells for Risk Stratification and Prevention.
Curr Oncol Rep. 2021 May 3;23(7):77. doi: 10.1007/s11912-021-01066-2.
8
Cardiovascular Complications of Pan-Cancer Therapies: The Need for Cardio-Oncology.
Cancers (Basel). 2023 Jun 5;15(11):3055. doi: 10.3390/cancers15113055.
9
Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do.
Cancers (Basel). 2022 Nov 2;14(21):5403. doi: 10.3390/cancers14215403.
10
QTc prolongation risk among patients receiving oral targeted antineoplastic medications: A real-world community-based oncology analysis.
Front Oncol. 2023 Mar 10;13:1098333. doi: 10.3389/fonc.2023.1098333. eCollection 2023.
本文引用的文献
1
Global Cardio Oncology Registry (G-COR): Registry Design, Primary Objectives, and Future Perspectives of a Multicenter Global Initiative.
Circ Cardiovasc Qual Outcomes. 2023 Oct;16(10):e009905. doi: 10.1161/CIRCOUTCOMES.123.009905. Epub 2023 Sep 13.
2
Advancing Cardio-Oncology in Asia.
Korean Circ J. 2023 Feb;53(2):69-91. doi: 10.4070/kcj.2022.0255.
3
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244.
4
Association Between Up-front Surgery and Risk of Stroke in US Veterans With Oropharyngeal Carcinoma.
JAMA Otolaryngol Head Neck Surg. 2022 Aug 1;148(8):740-747. doi: 10.1001/jamaoto.2022.1327.
5
QT Prolongation in Cancer Patients.
Front Cardiovasc Med. 2021 Feb 25;8:613625. doi: 10.3389/fcvm.2021.613625. eCollection 2021.
6
The incidence of myocardial infarction and stroke in head and neck cancer patients.
Sci Rep. 2021 Feb 18;11(1):4174. doi: 10.1038/s41598-021-83665-4.
7
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2021 Mar;32(3):309-322. doi: 10.1016/j.annonc.2020.11.014. Epub 2021 Feb 3.
8
From trends to transformation: where cardio-oncology is to make a difference.
Eur Heart J. 2019 Dec 21;40(48):3898-3900. doi: 10.1093/eurheartj/ehz781.
9
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report.
Biol Blood Marrow Transplant. 2017 Feb;23(2):201-210. doi: 10.1016/j.bbmt.2016.08.019. Epub 2016 Aug 30.
10
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).
Eur Heart J. 2016 Sep 21;37(36):2768-2801. doi: 10.1093/eurheartj/ehw211. Epub 2016 Aug 26.
Zotero 插件